TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02625805
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
Study: NCT00880620
Drug: IPX066 95 mg LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 capsule containing 95 mg LD/23.75 mg CD
Study: NCT00880620
Drug: IPX066 145 mg LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 capsule containing 145 mg LD/36.25 mg CD
Study: NCT00880620
Drug: IPX066 195 mg LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 capsule containing 195 mg LD/48.75 mg CD
Study: NCT00880620
Drug: IPX066 245 mg LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 capsule containing 245 mg LD/61.25 mg CD
Study: NCT02472782
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
Study: NCT01673828
Drug: Allopregnanolone injection
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Study: NCT04435483
Drug: Acalabrutinib Treatment A
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
Study: NCT04435483
Drug: Acalabrutinib Treatment B
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
Study: NCT04435483
Drug: Acalabrutinib Treatment C
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
Study: NCT03414658
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread
Study: NCT03414658
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Study: NCT03414658
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
Study: NCT03414658
Drug: Utomilumab
Normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Study: NCT00967317
Drug: Auris-Sedina
Normalized name: Ba-302 conjugated to monomethyl auristatin e
DrugBank: Ozuriftamab vedotin (DB17422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor.
Study: NCT01981837
Drug: ALN-TTRSC (revusiran) for subcutaneous administration
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534311
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
Study: NCT00360698
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One daily injection at bedtime
Study: NCT00360698
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At same dosage as during the run-in period
Study: NCT00360698
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One bolus given before the main meal
Study: NCT00360698
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At same dosage as during the run-in period
Study: NCT05255575
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive ertapenem therapy.
Study: NCT03082846
Drug: Temozolomide chemotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
Study: NCT04088032
Drug: Abemaciclib, durvalumab and aromatase inhibitor
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
Study: NCT00251459
Drug: rhuFab V2 (ranibizumab)
Normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03991936
Drug: Triamcinolone Acetonide 2.5 mg/mL
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/mL intralesional injection
Study: NCT03991936
Drug: Triamcinolone Acetonide 5.0 mg/mL
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 mg/mL intralesional injection
Study: NCT03991936
Drug: Triamcinolone Acetonide 7.5 mg/mL
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg/mL intralesional injection
Study: NCT03991936
Drug: Triamcinolone Acetonide 10 mg/mL
Normalized name: triamcinolone acetonide 10 MG/ML
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/mL intralesional injection
Study: NCT00269685
Drug: vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01877005
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00064363
Drug: talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02365805
Drug: Docetaxel + Ciclofosfamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
Study: NCT00728195
Drug: JNJ-37822681
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
Study: NCT00728195
Drug: JNJ-37822681
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
Study: NCT00728195
Drug: JNJ-37822681
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
Study: NCT00728195
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
Study: NCT03745989
Drug: MK-8353
Normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
Study: NCT03745989
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
Study: NCT03883581
Drug: dextromethorphan HBr and quinidine sulfate
Normalized name: dextromethorphan hydrobromide / quinidine sulfate Pill
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
Study: NCT02356913
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01015404
Drug: Trafermin
Normalized name: trafermin
DrugBank: Trafermin (DB06244)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered to the bone defect during flap operation
Study: NCT03073369
Drug: Ergocalciferol 50000 UNT
Normalized name: ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ergocalciferol 50000 IU once daily for 6 weeks
Study: NCT00287755
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
Study: NCT02367859
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03189329
Drug: 2% lidocaine hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Study: NCT02367859
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03189329
Drug: 0.5% levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Study: NCT00413777
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
Study: NCT01808196
Drug: Losartan Potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
Study: NCT03332459
Drug: Lumicitabine
Normalized name: Lumicitabine
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Study: NCT00362778
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous continuous insulin infusion for 48 hours
Study: NCT01832467
Drug: cetuximab-containing chemotherapy
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02354235
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT02354235
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00939341
Drug: Symbicort (Budesonide/Formoterol)
Normalized name: budesonide / formoterol Metered Dose Inhaler [Symbicort]
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Study: NCT00135408
Drug: Ipilimumab+ Placebo
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Study: NCT00135408
Drug: Ipilimumab+ Budesonide
Normalized name: Ipilimumab
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
Study: NCT02844322
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Study: NCT02844322
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Study: NCT04614636
Drug: FT538
Normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
Study: NCT04614636
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning Agent
Study: NCT02186275
Drug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
Study: NCT02280096
Drug: 4-aminopyridine
Normalized name: 4-aminopyridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
Study: NCT02186275
Drug: Vitamin D3 800 UI/day then 800 UI/day
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
Study: NCT04614636
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal Antibody, CD38, Anti-CD38
Study: NCT02952885
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
Study: NCT04614636
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal Antibody
Study: NCT01863706
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400µg oral misoprostol
Study: NCT01863706
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU Oxytocin
Study: NCT00060151
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04802928
Drug: Isoniazid 300 milligram
Normalized name: Product containing precisely isoniazid 300 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets 150 milligram b.i.d.
Study: NCT01948518
Drug: Oral sildenafil 20 mg
Normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
Study: NCT00116012
Drug: rNAPc2
Normalized name: rNAPc2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02919761
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 Units Acthar Gel per 1 mL for subcutaneous injection
Study: NCT02210728
Drug: methylphenidate or amphetamine product
Normalized name: amphetamine Oral Product
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
Study: NCT02967640
Drug: Ketalar
Normalized name: Ketalar
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
Study: NCT01037140
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral cholecalciferol tablets of 175 micrograms daily for 6 months
Study: NCT00676728
Drug: JNJ-26481585
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
Study: NCT01740713
Drug: Deferiprone, dose level 1
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a solution at 80 mg/mL will be administered orally
Study: NCT02282085
Drug: Aripiprazole Once-Monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04094896
Drug: TCHP
Normalized name: Trastuzumab, Carboplatin, Docetaxel, and Pertuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Study: NCT02039726
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 or 30 mg quizartinib tablets administered orally once daily
Study: NCT02865928
Drug: Bupivicaine HCl
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided serratus plane block with bupivicaine
Study: NCT01740713
Drug: Deferiprone, dose level 2
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a solution at 80 mg/mL will be administered orally
Study: NCT01740713
Drug: Deferiprone, dose level 3
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a solution at 80 mg/mL will be administered orally
Study: NCT00712335
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DPI 250 mcg BID for 3 weeks
Study: NCT00712335
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO 10 mg QHS for 3 weeks
Study: NCT00712335
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI 50mg BID for 3 weeks
Study: NCT00855686
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg once daily oral dose